Lars Wahlberg, MD, PhD
CEO/CMO
Neurosurgeon, translational scientist, and entrepreneur
>20 years of biotechnology R&D experience in developing biologics-based therapies for neurological disorders
Superscript
Brain Repair Is Our Mission
Novel therapies for neuropathic pain and devastating disorders of the nervous system
ABout OUR MISSION
What we do make perfect sense
Today's treatments are either inadequate or non-existing and the extent of human suffering cannot be described with words.
new therapies are a must, and we are coMmitted to make a change!
ApproacH AND TECHNOLOGIES
Precision from patient to treatment
Millions of years of evolution can hardly be wrong. We develop precise biotherapeutics based on human proteins that through the evolution have been optimized for neuronal repair and function.
Our reparative biotherapeutics are tailored for disease subtypes diagnosed by biomarkers, pathology and genetics.
The biotherapeutics are delivered either by injection or locally by an implantable proprietary gene therapy device to facilitate the most efficient treatment of the disease.
ABout Us
Change through innovation
We are a clinical stage company motivated by the need to transform the treatments of patients suffering from pain and devastating neurological diseases.
Building on an innovative tradition in science with deep roots in the Karolinska institute, we develop next generation biotherapeutics.
We have footprints in both Sweden and US to facilitate our global presence, research collaborations, and partnering to deliver value for patients and investors
Product Pipeline
New Generations Biotherapeutics
Our clinical candidate NeuRepair targets neuropathic pain with a novel mechanism and has demonstrated promising efficacy in patients suffering from painful lumbar radiculopathy, PLR (sciatica).
NeuRepair is poised to become the first-in-class therapy for neuropathic pain affecting millions of patients.
Based on recombinant biologics and our proprietary gene therapy device platform, we have generated a pipeline of additional reparative products in preclinical development for multiple indications including Epilepsy and Parkinson's disease.
Our Leadership Team
Johan Lundkvist, As. Prof
COO/CSO
Neurobiologist and cellbiologist by training
Associate Professor at Karolinska Institute in 2005
>17 years industrial leadership experience from small biotech start-ups and large pharma within neurological disorders
An van Es-Johansson, MD
Head Clinical Development
Physician , entrepreneur with extensive Board experience
> 30 years international experience in big pharma and biotech companies with focus on Clinical Development, Regulatory and Pharmacovigilance
Bob Blomquist
Corporate Development
Business leader with operational experience in Fortune 500 and new venture startups
>35 years of healthcare industry experience, including biopharmaceuticals, diagnostics and medical devices
Advisor to private equity and biopharma
Kristofer Svensson, B.Sc
CFO
B.Sc in Business Administration and Economics
Held several executive finance positions in the medtech field Since 2017.
Thomas Pollare, MD, PhD
Chairman<<
Experienced advisor and investor, including partner and member of 3i Global Healthcare team
> 25 years health care industry experience with several executive positions in major pharma companies and smaller biotechs
Experience from over 30 board positions
NEWS
Oct 7th 2021 Lars Wahlberg, CEO, presents at Vator Innovation Summit
Contact
Sinfonia Biotherapeutics AB
Hälsovägen 7, 14157 Huddinge, Sweden
130 Franklin Street, STE2,Warren, RI, US
info@sinfoniabtx.com